Second, whether good control of plasma galectin-3 levels resulting from medication such as SGLT2 or ARNI in patients with heart failure with a preserved ejection fraction further enhances the survival prognosis in this group of patients is still unknown. The gene discussed is LGALS3; the disease is heart failure.